Evidence map›Paper›PMID 23677874›Full record

Trial reportPediatric blood & cancer2013

Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy.

Alison M Friedmann, Julie A Wolfson, Melissa M Hudson, Howard J Weinstein, Michael P Link, Amy Billett, Eric C Larsen, Torunn Yock, Sarah S Donaldson, Karen Marcus and 3 more

Abstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Pediatric blood & cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Alison M FriedmannMassachusetts General Hospital, Boston, Massachusetts 02114, USA. afriedmann@partners.org
Julie A Wolfson
Melissa M Hudson
Howard J Weinstein
Michael P Link
Amy Billett
Eric C Larsen
Torunn Yock
Sarah S Donaldson
Karen Marcus
Matthew J Krasin
Scott C Howard
Monika L Metzger
St. Jude Children's Research Hospital · USMassachusetts General Hospital · USDana-Farber Cancer Institute · USStanford Medicine · USCity Of Hope National Medical Center · USNew England Cancer Specialists · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Oncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6M
NCI NIH HHS CA-21765NCI NIH HHS K12 CA001727NCI NIH HHS P30 CA021765
6 · The paper itself

Abstract

backgroundThe outcome of treatment for pediatric Hodgkin lymphoma (HL) is excellent using chemotherapy and radiation. However, a minority of patients will relapse after treatment, but additional therapy achieves durable second remission in many cases. The optimal surveillance strategy after modern therapy for HL has not been well defined. PROCEDURES: We reviewed the outcomes of pediatric patients with HL treated between 1990 and 2006 to determine the primary event that led to the detection of relapse. We determined the probability of relapse detection by routine follow-up procedures, including history, physical examination, laboratory tests, and imaging, and determined the impact of each of these screening methods on the likelihood of survival after relapse.

resultsRelapse occurred in 64 of 402 evaluable patients (15.9%) at a median of 1.7 years from the time of diagnosis. The majority of relapses (60%) were diagnosed at a routine visit, and patient complaint was the most common initial finding that led to a diagnosis of relapse (47% of relapses). An abnormal finding on physical examination was the primary event in another 17% of relapses, and imaging abnormalities led to the diagnosis in the remaining 36%. Laboratory abnormalities were never the primary finding. The method of detection of relapse and timing (whether detected at a routine visit or an extra visit) did not impact survival.

conclusionsIn pediatric HL, most relapses are identified through history and physical examination. Frequent imaging of asymptomatic patients does not appear to impact survival and is probably not warranted.

Indexed as

AdolescentAdultChildChild, PreschoolDisease-Free SurvivalFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleRecurrenceRetrospective StudiesSurvival RatechildhoodHodgkin lymphomaoutcomepediatricrelapsesurveillance

Identifiers

PMID23677874
PMCPMC4313350
OpenAlexW2132646523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.